World Health Organization

Research on Marburg candidate vaccines and therapeutics

14 July 2022

16:00 – 18:15 Central European Time CET

DRAFT Agenda

R&DBlueprint

Powering research
to prevent epidemics

OBJECTIVES OF THE MEETING

The WHO R&D Blueprint is organizing an urgent meeting with the MARVAC partners next Thursday **July 14th from 16:00-18:15** CET (Geneva time) to discuss research activities related to MARV cases in Ghana.

MARVAC is a WHO-coordinated consortium to promote international collaboration for the development of MVD vaccines.

This WHO-coordinated consortium for the development of MARV vaccines (MARVAC) is based on the same sharing principles that governed the scientific interactions of the WHO COVID-19 working groups, that helped to accelerate the development of COVID-19 vaccines and therapeutics.

The consortium builds on the success of WHO working groups on COVID-19 preclinical models and assays that, through rapid sharing of scientific findings and protocols accelerated the development of COVID-19 vaccines.

To make this consortium as effective as possible, it includes shareholders from industry (all vaccine and therapeutic developers), non-profit organizations, government, and academia.
This joint venture is supported by the following principles:
Sharing of assays and reagents,
promoting access to laboratory networks in MVD endemic countries and
promoting structural support for preclinical development of upcoming MVD vaccine and therapeutic candidates.

Chairperson: Phil Krause

Time	Topic	Proposed Speakers
16:00 – 16:05	**Welcome address** Objectives of the meeting	Ana Maria Henao-Restrepo (WHO)
16:05 – 16:15	Marburg epidemiology (most recent outbreaks)	Fiona Braka TBC (WHO AFRO)
16:15 – 16:30	Situation report and laboratory networks	JH Kofi Bonney and John Odoom (Noguchi Memorial Institute, Ghana)
Session 1. What candidate vaccines are in the pipeline and how many clinical grade doses are available?		
16:30 -17:05	Updates on vaccine development status and clinical grade doses available	Representatives from vaccine developers o Auro Vaccines o EBSI o JNJ o PHVaccines o Sabin o BARDA o IAVI
17:05 – 17:15	Platform trial design for preventive vaccines against Marburg virus	Ira Longini (Univ of Florida)
17:15-17:30	The way forward o How to decide which vaccine(s) are tested first (transparent process)? o What additional scientific steps should be taken to set up the platform trial (if the outbreak is confirmed)?	Plenary discussion
Session 2. What candidate therapeutics are in the pipeline and how many clinical grade doses are available?		
17:30 – 17:50	Updates on therapeutics development status and clinical grade doses available	Representatives from therapeutics developers o mAb therapy (Larry Zeitlin, Mappbio) o Marburg virus PEP (Tom Geisbert, UTMB) o Small molecules (Elizabeth Lapatovich, JPM CBRN MED)
17:50 – 18:00	The way forward o How to decide which therapeutics(s) are tested first (transparent process)? o What additional scientific steps should be taken to set up the platform trial (if the outbreak is confirmed)?	Plenary discussion
18:00 – 18:15	Conclusions & Next Steps	WHO
18:15	**END OF MEETING**	